Need professional-grade analysis? Visit stockanalysis.com
$2.20B
N/A
N/A
N/A
Oruka Therapeutics, Inc. (ORKA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $68.92, up 2.76% from the previous close.
Over the past year, ORKA has traded between a low of $9.29 and a high of $68.92. The stock has gained 551.4% over this period. It is currently 641.9% above its 52-week low.
Oruka Therapeutics, Inc. has a market capitalization of $2.20B.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Side-by-side comparison against top Healthcare peers.